Remdesivir to come in oral formulation; drug regulator s nod awaited
Jubilant Pharma says oral formulation is an affordable, more convenient, easy-to-administer and potentially effective treatment option for COVID-19 patients
BusinessToday.In | April 19, 2021 | Updated 13:13 IST
Remdesivir is the first and the only antiviral drug fully approved by the US FDA
Jubilant Pharma Limited, a subsidiary of Jubilant Pharmova Limited, has completed safety trials in animals and healthy human volunteers in India using a novel oral formulation of remdesivir, which is likely to be more effective and viable than the commercially available injectable formulation. Jubilant has now sought approval for additional studies for this novel oral formulation from the Drug Controller General of India (DCGI).